Yu-Chiau Shyu

Prof. Yu-Chiau Shyu

Community Medicine Research Center, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1997 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
YCYi-Wen Chu
Yi-Wen Chu
PYPan-Chyr Yang
Pan-Chyr Yang
SYShuenn-Chen Yang
Shuenn-Chen Yang
YSYu-Chiau Shyu
Yu-Chiau Shyu
MHMary J. C. Hendrix
Mary J. C. Hendrix
CWCheng-Wen Wu
Cheng-Wen Wu
To better understand the mechanism(s) underlying lung cancer invasion and metastasis, a Transwell invasion chamber was used to select progressively more invasive cancer cell populations from a clonal cell line of human lung adenocarcinoma, CL1. Five sublines with progressive invasiveness, designated CL1-1, CL1-2, CL1-3, CL1-4, and CL1-5, were obtained through this in vitro selection process. Their invasive abilities through basement membrane matrix showed a 4- to 6-fold increase over that of the parental cells. Moreover, the sublines manifested an increase in their colony-forming ability on soft agar, tumorigenicity, and metastatic potency in severe combined immunodeficiency (SCID) mice. Examining the phenotypes of the cell lines revealed increased expression of 92 kD gelatinase and an increase in the cell population stained with anti-keratin-8 and -18 antibodies. Clonal isolation of anti-keratin-18-antibody-positive and -negative cell populations demonstrated a correlated enhancement of the invasiveness of these cells and their expression of keratin-18. These results support the notion that the metastatic behavior of lung cancer cells can be characterized with this in vitro system, and that the properties of these progressively invasive cancer cells can be clonally studied.

14 May 2017 in Acta Psychiatrica Scandinavica
Verified
Journal Article
Closed access
PDF file
CBChristian J Bachmann
Christian J Bachmann
LAL. Aagaard
L. Aagaard
MBMiquel Bernardo
Miquel Bernardo
LBL. Brandt
L. Brandt
MCM. Cartabia
M. Cartabia
DTD. Taylor
D. Taylor

1 October 2017 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
ÓHÓskar Hálfdánarson
Óskar Hálfdánarson
HZHelga Zoëga
Helga Zoëga
LALise Aagaard
Lise Aagaard
MBMiquel Bernardo
Miquel Bernardo
LBLena Brandt
Lena Brandt
CBChristian J Bachmann
Christian J Bachmann

1 August 2019 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
MMMyrela O. Machado
Myrela O. Machado
VSVicky Stergiopoulos
Vicky Stergiopoulos
MMMichael Maes
Michael Maes
PKPaul A. Kurdyak
Paul A. Kurdyak
PLPao-Yen Lin
Pao-Yen Lin
Andre CarvalhoAndre Carvalho
Andre Carvalho
Hidradenitis suppurativa (HS) is a chronic recurrent inflammatory skin disease with a characteristic clinical presentation of painful and suppurating lesions in apocrine-gland bearing intertriginous regions.1 The prevalence of HS varies between 0.05% to 4.00% depending on the methodology used to estimate the prevalence and the population studied.2 Hidradenitis suppurativa commonly affects young populations with a female to male ratio of 3:1. It is associated with significant disability,3-5 impaired quality of life,5-7 sexual dysfunction,8 and disturbed body image.9 Furthermore, patient perspectives of living with HS convey physical, psychological, social, and emotional distress.4

25 January 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
THTing-Shuo Huang
Ting-Shuo Huang
YSYu-Chiau Shyu
Yu-Chiau Shyu
HCHuang-Yang Chen
Huang-Yang Chen
LLLi-Mei Lin
Li-Mei Lin
CLChia-Ying Lo
Chia-Ying Lo
PCPei-Jer Chen
Pei-Jer Chen
It is currently unclear whether parenteral selenium supplementation should be recommended in the management of critically ill patients. Here we conducted a systematic review and meta-analysis to assess the efficacy of parenteral selenium supplementation on clinical outcomes. Randomized trials investigating parenteral selenium supplementation administered in addition to standard of care to critically ill patients were included. CENTRAL, Medline, EMBASE, the Science Citation Index, and CINAHL were searched with complementary manual searches. The primary outcome was all-cause mortality. Trials published in any language were included. Two authors independently extracted data and assessed trial quality. A third author was consulted to resolve disagreements and for quality assurance. Twelve trials were included and meta-analysis was performed on nine trials that recruited critically ill septic patients. These comprised 965 participants in total. Of these, 148 patients (30.7%) in the treatment groups, and 180 patients (37.3%) in control groups died. Parenteral selenium treatment significantly reduced all-cause mortality in critically ill patients with sepsis (relative risk [RR] 0.83, 95% CI 0.70–0.99, p = 0.04, I2 = 0%). Subgroup analyses demonstrated that the administration schedule employing longer duration (RR 0.77, 95% CI 0.63–0.94, p = 0.01, I2 = 0%), loading boluses (RR 0.73, 95% CI 0.58–0.94, p = 0.01, I2 = 0%) or high-dose selenium treatment (RR 0.77, 95% CI 0.61–0.99, p = 0.04, I2 = 0%) might be associated with a lower mortality risk. There was no evidence of adverse events. Parenteral selenium supplementation reduces risk of mortality among critically ill patients with sepsis. Owing to the varied methodological quality of the studies, future high-quality randomized trials that directly focus on the effect of adequate-duration of parenteral selenium supplementation for severe septic patients are needed to confirm our results. Clinicians should consider these findings when treating this high-risk population. PROSPERO 2011; CRD42011001768

1 November 2017 in Cell Reports
Verified
Journal Article
Open access
ZSZhao-Qing Shen
Zhao-Qing Shen
YCYi-Fan Chen
Yi-Fan Chen
JCJim-Ray Chen
Jim-Ray Chen
YJYuh-Shan Jou
Yuh-Shan Jou
PWPei-Chun Wu
Pei-Chun Wu
TTTing Fen Tsai
Ting Fen Tsai
CISD2 is located within the chromosome 4q region frequently deleted in hepatocellular carcinoma (HCC). Mice with Cisd2 heterozygous deficiency develop a phenotype similar to the clinical manifestation of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Cisd2 haploinsufficiency causes a low incidence (20%) of spontaneous HCC and promotes HBV-associated and DEN-induced HCC; conversely, 2-fold overexpression of Cisd2 suppresses HCC in these models. Mechanistically, Cisd2 interacts with Serca2b and mediates its Ca2+ pump activity via modulation of Serca2b oxidative modification, which regulates ER Ca2+ uptake and maintains intracellular Ca2+ homeostasis in the hepatocyte. CISD2 haploinsufficiency disrupts calcium homeostasis, causing ER stress and subsequent NAFLD and NASH. Hemizygous deletion and decreased expression of CISD2 are detectable in a substantial fraction of human HCC specimens. These findings substantiate CISD2 as a haploinsufficient tumor suppressor and highlights Cisd2 as a drug target when developing therapies to treat NAFLD/NASH and prevent HCC.